Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies

Journal of Rheumatology

Volumn 29, Issue 8, 2002, Pages 1683-1688

  Chopra, Nikhil ^a   Koren, Sharon ^a   Greer, Wenda L ^a   Fortin, Paul R ^a   Rauch, Joyce ^a   Fortin, Isabelle ^a   Senécal, Jean Luc ^a   Docherty, Peter ^a   Hanly, John G ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antiphospholipid antibodies; Factor V Leiden; Prothrombin gene mutation

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; BLOOD CLOTTING FACTOR 5;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; HUMAN; MALE; MIDDLE AGE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTHROMBIN; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; THROMBOSIS; HUMANS; MIDDLE AGED;

EID: 0036021145     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Update on antiphospholipid antibodies
2. Antiphospholipid syndrome: Antibodies and antigens
3. Lupus anticoagulants and antiphospholipid antibodies
4. Lupus anticoagulant antibodies: Recognition of phospholipid-binding protein complexes
5. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
6. Validation of the Sapporo criteria for antiphospholipid syndrome
7. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives
8. Comparison of the risk of pulmonary embolism and deep vein thrombosis in the presence of factor V Leiden or prothrombin G20210A
9. Epidemiology of factor V Leiden: Clinical implications
10. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease
11. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
12. Hypercoagulability in various autoimmune diseases: No association with factor V Leiden mutation
13. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children
14. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation
15. Association of primary antiphospholipid syndrome with inherited activated protein C resistance
16. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies
17. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus
18. Criteria for the diagnosis of lupus anticoagulants: An update
19. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
20. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome
21. Factor V Arg506 → Gln mutation in patients with antiphospholipid antibodies
22. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
23. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
24. Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome
25. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies
26. Oral contraceptives in systemic lupus erythematosus: Side-effects and influence on the activity of SLE
27. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis
28. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies
29. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant
30. Anticardiolipin antibodies: A study in cerebral venous thrombosis
31. Prevalence of anticardiolipin antibodies in peripheral arterial thrombosis